The DOI matches its Crossref record; 279 of the 279 references it cites were found in a registry or an index.
Therapeutic targeting of EPH receptors and their ligands
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Wang, H. U., Chen, Z.-F., & Anderson, D. J. (1998) · Cell · doi:10.1016/s0092-8674(00)81436-1 · Cited by 1,669
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis
Wang, Y., Nakayama, M., Pitulescu, M. E., Schmidt, T. S., Bochenek, M. L., Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Lüthi, U., et al. (2010) · Nature · doi:10.1038/nature09002 · Cited by 1,271
Eph-Ephrin Bidirectional Signaling in Physiology and Disease
Pasquale, E. B. (2008) · Cell · doi:10.1016/j.cell.2008.03.011 · Cited by 1,252
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2806 · Cited by 1,226
Batlle, E., Henderson, J. T., Beghtel, H., van den Born, M. M. W., Sancho, E., Huls, G., Meeldijk, J., Robertson, J., van de Wetering, M., Pawson, T., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01015-2 · Cited by 1,120
Research works printed but not linked: 26
- Marquardt, T. et al. Coexpressed EphA receptors and ephrin-A ligands mediate opposing actions on growth cone navigation from distinct membrane domains. Cell 121, 127–139 (2005). · doi:10.1016/j.cell.2005.01.020
- Gu, C. & Park, S. The EphA8 receptor regulates integrin activity through p110γ phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent manner. Mol. Cell. Biol. 21, 4579–4597 (2001). · doi:10.1128/mcb.21.14.4579-4597.2001
- Wimmer-Kleikamp, S. H. et al. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 112, 721–732 (2008). · doi:10.1182/blood-2007-11-121681
- Dopeso, H. et al. The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res. 69, 7430–7438 (2009). · doi:10.1158/0008-5472.can-09-0706
- Hagey, A. et al. A recombinant antibody to EphA3 for the treatment of hematologic malignancies: research update and interim Phase 1 study results. Blood (ASH Annual Meeting Abstracts) 118, 4893 (2011).
- Dawson, D. W. et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 26, 4243–4252 (2007). · doi:10.1038/sj.onc.1210211
- Wang, J. et al. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum. Pathol. 38, 1649–1656 (2007). · doi:10.1016/j.humpath.2007.01.030
- Guan, M., Xu, C., Zhang, F. & Ye, C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int. J. Cancer 124, 88–94 (2009). · doi:10.1002/ijc.23890
- Nievergall, E., Saunders, T. & Lackmann, M. Targeting of EPH receptor tyrosine kinases for anticancer therapy. Crit. Rev. Oncog. 17, 211–232 (2012). · doi:10.1615/critrevoncog.v17.i2.60
- Palath, V. et al. A recombinant antibody to EphA3 with pro-apoptotic and enhanced ADCC activity against various hematologic malignancies shows selective inhibition of colony formation from long-term culture-initiating cells (LTC-ICs) in primary leukemia samples. Blood (ASH Annual Meeting Abstracts) 116, 2897 (2010).
- Heroult, M. et al. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2. Mol. Cancer Res. 8, 1297–1309 (2010). · doi:10.1158/1541-7786.mcr-09-0453
- Scehnet, J. S. et al. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 113, 254–263 (2009). · doi:10.1182/blood-2008-02-140020
- Noblitt, L. W., Bangari, D. S., Shukla, S., Mohammed, S. & Mittal, S. K. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther. 12, 46–53 (2005). · doi:10.1038/sj.cgt.7700763
- Wakelee, H. A. et al. A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). J. Clin. Oncol. 24, Abstr. 3044 (2006). · doi:10.1200/jco.2006.24.18_suppl.3044
- Bardelle, C. et al. Inhibitors of the tyrosine kinase EphB4. Part 1: structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. Bioorg. Med. Chem. Lett. 18, 2776–2780 (2008). · doi:10.1016/j.bmcl.2008.04.015
- Jin, M. et al. Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci. 99, 1656–1662 (2008). · doi:10.1111/j.1349-7006.2008.00866.x
- Irizarry-Ramirez, M. et al. Upregulation of EphA3 receptor after spinal cord injury. J. Neurotrauma 22, 929–935 (2005). · doi:10.1089/neu.2005.22.929
- Arocho, L. C. et al. Expression profile and role of EphrinA1 ligand after spinal cord injury. Cell. Mol. Neurobiol. 31, 1057–1069 (2011). · doi:10.1007/s10571-011-9705-2
- Lickliter, J. D., Smith, F. M., Olsson, J. E., Mackwell, K. L. & Boyd, A. W. Embryonic stem cells express multiple Eph-subfamily receptor tyrosine kinases. Proc. Natl Acad. Sci. USA 93, 145–150 (1996). · doi:10.1073/pnas.93.1.145
- Lazarova, P. et al. Growth factor receptors in hematopoietic stem cells: EPH family expression in CD34+ and CD133+ cell populations from mobilized peripheral blood. Int. J. Immunopathol. Pharmacol. 19, 49–56 (2006). · doi:10.1177/205873920601900105
- Luo, H., Yu, G., Tremblay, J. & Wu, J. EphB6-null mutation results in compromised T cell function. J. Clin. Invest. 114, 1762–1773 (2004). · doi:10.1172/jci21846
- Baldwin, C. et al. Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinases. Am. J. Physiol. Renal Physiol. 291, F960–F971 (2006). · doi:10.1152/ajprenal.00020.2006
- Cercone, M. A., Schroeder, W., Schomberg, S. & Carpenter, T. C. EphA2 receptor mediates increased vascular permeability in lung injury due to viral infection and hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L856–L863 (2009). · doi:10.1152/ajplung.00118.2009
- Tournoij, E. et al. The platelet P2Y12 receptor contributes to granule secretion through Ephrin A4 receptor. Platelets 23, 617–625 (2012). · doi:10.3109/09537104.2011.645924
- Hayashi, S., Asahara, T., Masuda, H., Isner, J. M. & Losordo, D. W. Functional ephrin-B2 expression for promotive interaction between arterial and venous vessels in postnatal neovascularization. Circulation 111, 2210–2218 (2005). · doi:10.1161/01.cir.0000163566.07427.73
- Zhao, X. et al. Vaccines targeting tumor blood vessel antigens promote CD8+ T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J. Immunol. 188, 1782–1788 (2012). · doi:10.4049/jimmunol.1101644
Cited by
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584
“Ephrin receptors are the largest family of receptor tyrosine kinases (Boyd et al., 2014).”
BackgroundMechanisms of ephrin–Eph signalling in development, physiology and disease
Kania, A., & Klein, R. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.16 · Cited by 643
Eph Receptors and Ephrins: Therapeutic Opportunities
Barquilla, A., & Pasquale, E. B. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140226 · Cited by 294
Barcoded viral tracing of single-cell interactions in central nervous system inflammation
Clark, I. C., Gutiérrez-Vázquez, C., Wheeler, M. A., Li, Z., Rothhammer, V., Linnerbauer, M., Sanmarco, L. M., Guo, L., Blain, M., Zandee, S. E. J., et al. (2021) · Science · doi:10.1126/science.abf1230 · Cited by 285
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269
Metadata
- Authors
- Boyd, A. W., Bartlett, P. F., & Lackmann, M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-12-31
- Volume
- 13
- Issue
- 1
- Pages
- 39-62
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2038385234
- Cited by
- 341
- References
- 279
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic targeting of EPH receptors and their ligands. https://app.cochat.ai/papers/10.1038/nrd4175
- The paper
- Boyd, A. W., Bartlett, P. F., & Lackmann, M. (2014). Therapeutic targeting of EPH receptors and their ligands. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd4175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.